Vol 9, No 1 (2023)
Review paper
Published online: 2023-03-21

open access

Page views 454
Article views/downloads 247
Get Citation

Connect on Social Media

Connect on Social Media

Risk factors for lipid disorders in systemic lupus erythematosus

Ewelina Kowynia1, Bogna Grygiel-Górniak1, Włodzimierz Samborski1
Rheumatology Forum 2023;9(1):14-22.


Systemic lupus erythematosus (SLE) is one of the autoimmune diseases of the connective tissue system with multi-organ involvement. Dyslipidemia in SLE results from the increased risk of cardiovascular diseases typical in the general population. Still, it is exacerbated by inflammation and medications (particularly glucocorticosteroids). In the course of SLE, lipid disorders are related to the disease activity and result from cardiovascular risk factors typical for the general population. During the therapy, it is recommended to control the lipid profile and modify the lifestyle risk factors (implement a properly balanced diet and appropriate physical activity). The role of immunosuppressive and immunomodulating therapy in SLE, which may have a pro-or anti-atherogenic effect, is also emphasized. Thus, the assessment of the dyslipidemia type in this disease is crucial. Proper hypolipemic treatment not only reduces the risk of cardiovascular disease but also affects the survival of patients.

Article available in PDF format

View PDF Download PDF file


  1. Stępień-Wyrobiec O, Derejczyk J, Wyrobiec G. Systemic lupus erythematosus in the elderly. Geriatria. 2009; 3: 139–146.
  2. Prokop E, Samborski W. Rola polimorfizmów pojedynczego nukleotydu w patogenezie tocznia rumieniowatego układowego [article in Polish]. Forum Reumatol. 2020; 6(3): 139–142.
  3. Rekvig OP. Systemic lupus erythematosus: definitions, contexts, conflicts, enigmas. Front Immunol. 2018; 9: 387.
  4. Rovenský J, Tuchynová A. Systemic lupus erythematosus in the elderly. Autoimmun Rev. 2008; 7(3): 235–239.
  5. Gustafsson JT, Svenungsson E. Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. Autoimmunity. 2014; 47(2): 67–76.
  6. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006; 54(8): 2550–2557.
  7. Borchers AT, Naguwa SM, Shoenfeld Y, et al. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev. 2010; 9(5): A277–A287.
  8. Petri M, Genovese M, Engle E, et al. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum. 1991; 34(8): 937–944.
  9. Swacha M, Więsik-Szewczyk E, Olesińska M. Cardiovascular risk assessment in patients with systemic lupus erythematosus: practical aspects. Reumatologia. 2011; 49(6): 419–425.
  10. Jankowski P, Czarnecka D, Wolfshaut-Wolak R, et al. Secondary prevention of coronary artery disease in contemporary clinical practice. Cardiol J. 2015; 22(2): 219–226.
  11. Jha SB, Rivera AP, Flores Monar GV, et al. Systemic lupus erythematosus and cardiovascular disease. Cureus. 2022; 14(2): e22027.
  12. Aviña-Zubieta JA, To F, Vostretsova K, et al. Risk of myocardial infarction and stroke in newly diagnosed systemic lupus erythematosus: a general population-based study. Arthritis Care Res (Hoboken). 2017; 69(6): 849–856.
  13. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997; 145(5): 408–415.
  14. Gwiazda E, Mastalerz-Migas A, Szyber P. Analysis of the incidence of various lipid disorders in patients with diagnosed dislipidemia. Family Medicine and Primary Care Review. 2014; 16(2): 101–102.
  15. Wajed J, Ahmad Y, Durrington PN, et al. Prevention of cardiovascular disease in systemic lupus erythematosus — proposed guidelines for risk factor management. Rheumatology (Oxford). 2004; 43(1): 7–12.
  16. Grabańska K, Kręgielska-Narożna M, Bogdański P, et al. The latest diagnostic and therapeutic standards dyslipidemia [article in Polish]. Forum Zaburzeń Metabolicznych. 2012; 3(3): 115–124.
  17. Katsiki N, Nikolic D, Montalto G, et al. The role of fibrate treatment in dyslipidemia: an overview. Curr Pharm Des. 2013; 19(17): 3124–3131.
  18. Wełnicki M, Janiszewski M, Mamcarz A. 10 powodów, dla których warto stosować kojarzenie statyny i ezetymibu. Medycyna FAKTÓW. 2018; 11(3): 176–180.
  19. Fried SK, Rao SP. Sugars, hypertriglyceridemia, and cardiovascular disease. Am J Clin Nutr. 2003; 78(4): 873S–880S.
  20. Szczęch R, Narkiewicz K. Zaburzenia lipidowe. Choroby Serca i Naczyń. 2008; 5(4): 227–228.
  21. Prenner SB, Mulvey CK, Ferguson JF, et al. Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides. Atherosclerosis. 2014; 236(2): 244–250.
  22. Pappan N, Rehman A. Dyslipidemia. Free Books & Documents 2021.
  23. Gau GT, Wright RS. Pathophysiology, diagnosis, and management of dyslipidemia. Curr Probl Cardiol. 2006; 31(7): 445–486.
  24. Szabó MZ, Szodoray P, Kiss E. Dyslipidemia in systemic lupus erythematosus. Immunol Res. 2017; 65(2): 543–550.
  25. Esteve E, Ricart W, Fernández-Real JM. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin Nutr. 2005; 24(1): 16–31.
  26. Sniderman AD, Williams K, Contois JH, et al. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes. 2011; 4(3): 337–345.
  27. Walldius G, Jungner I, Holme I, et al. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001; 358(9298): 2026–2033.
  28. Borba EF, Bonfá E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus. 1997; 6(6): 533–539.
  29. Yuan J, Li LI, Wang Z, et al. Dyslipidemia in patients with systemic lupus erythematosus: Association with disease activity and B-type natriuretic peptide levels. Biomed Rep. 2016; 4(1): 68–72.
  30. Wijaya LK, Kasjmir YI, Sukmana N, et al. The proportion of dyslipidemia in systemic lupus erythematosus patient and distribution of correlated factors. Acta Med Indones. 2005; 37(3): 132–144.
  31. Tselios K, Koumaras C, Gladman D, et al. Dyslipidemia in systemic lupus erythematosus: just another comorbidity? Seminars in Arthritis and Rheumatism. 2016; 45(5): 604–610.
  32. Coelewij L, Waddington K, Robinson G, et al. Using serum metabolomics analysis to predict sub-clinical atherosclerosis in patients with SLE. Arterioscler Thromb Vasc Biol. 2021; 41(4): 1446–1458.
  33. Gunawan H, Awalia A, Soeroso J. Dyslipidemia and disease avtivity in systemic lupus erythematous: an independent risk factor. Lupus. 2017; 4(1): 1–227.
  34. Genest J, Libby P, Gotto AM. Zaburzenia lipoprotein a choroby układu krążenia. In: Zipes DP, Libby P, Bonow PO, Braunwald E. ed. Choroby serca. Elsevier Urban & Partner, Wrocław 2007: 985–1005.
  35. de Carvalho JF, Borba EF, Viana VS, et al. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? Arthritis Rheum. 2004; 50(11): 3610–3615.
  36. Wożakowska-Kapłon B, Barylski M, Salwa P, et al. Zalecenia postępowania w dyslipidemii — propozycja algorytmu dla lekarzy rodzinnych. Forum Medycyny Rodzinnej. 2012; 6(6): 261–282.
  37. Klack K, Bonfa E, Borba Neto EF. Diet and nutritional aspects in systemic lupus erythematosus. Rev Bras Reumatol. 2012; 52(3): 384–408.
  38. Aparicio-Soto M, Sánchez-Hidalgo M, Alarcón-de-la-Lastra C. An update on diet and nutritional factors in systemic lupus erythematosus management. Nutr Res Rev. 2017; 30(1): 118–137.
  39. Shah M, Kavanaugh A, Coyle Y, et al. Effect of a culturally sensitive cholesterol lowering diet program on lipid and lipoproteins, body weight, nutrient intakes and quality of life in patients with sytemic lupus erythematosus. J Rheumatol. 2002; 29(10): 2122–2128.
  40. Mirabelli G, Cannarile F, Bruni C, et al. One year in review 2015: systemic lupus eythematosus. Clin Exp Rheumatol. 2015; 33(3): 414–425.
  41. Grygiel-Górniak B, Thiem A, Samborski W. Znaczenie witaminy D w układowych chorobach tkanki łącznej. Rheumatol Forum. 2021; 7(2): 55–64.
  42. Wahono CS, Rusmini H, Soelistyoningsih D, et al. Effects of 1,25(OH)2D3 in immune response regulation of systemic lupus erithematosus (SLE) patient with hypovitamin D. Int J Clin Exp Med. 2014; 7(1): 22–31.
  43. Handono K, Sidarta YO, Pradana BA, et al. Vitamin D prevents endothelial damage induced by increased neutrophil extracellular traps formation in patients with systemic lupus erythematosus. Acta Med Indones. 2014; 46(3): 189–198.
  44. Mahto H, Tripathy R, Das BK, et al. Association between vitamin D receptor polymorphisms and systemic lupus erythematosus in an Indian cohort. Int J Rheum Dis. 2018; 21(2): 468–476.
  45. Ayán C, Martín V. Systemic lupus erythematosus and exercise. Lupus. 2007; 16(1): 5–9.
  46. Lee IH, Ryu YU. Physical therapy combined with corticosteroid intervention for systemic lupus erythematosus with central nervous system involvement: a case report. J Phys Ther Sci. 2014; 26(11): 1839–1841.
  47. Sharif K, Watad A, Bragazzi NL, et al. Physical activity and autoimmune diseases: Get moving and manage the disease. Autoimmun Rev. 2018; 17(1): 53–72.
  48. Pinto AJ, Roschel H, de Sá Pinto AL, et al. Physical inactivity and sedentary behavior: Overlooked risk factors in autoimmune rheumatic diseases? Autoimmun Rev. 2017; 16(7): 667–674.
  49. O'Dwyer T, Durcan L, Wilson F. Exercise and physical activity in systemic lupus erythematosus: A systematic review with meta-analyses. Semin Arthritis Rheum. 2017; 47(2): 204–215.
  50. Fangtham M, Kasturi S, Bannuru RR, et al. Non-pharmacologic therapies for systemic lupus erythematosus. Lupus. 2019; 28(6): 703–712.
  51. Mahieu MA, Ahn GE, Chmiel JS, et al. Fatigue, patient reported outcomes, and objective measurement of physical activity in systemic lupus erythematosus. Lupus. 2016; 25(11): 1190–1199.
  52. Eriksson K, Svenungsson E, Karreskog H, et al. Physical activity in patients with systemic lupus erythematosus and matched controls. Scand J Rheumatol. 2012; 41(4): 290–297.
  53. Boström C, Dupré B, Tengvar P, et al. Aerobic capacity correlates to self-assessed physical function but not to overall disease activity or organ damage in women with systemic lupus erythematosus with low-to-moderate disease activity and organ damage. Lupus. 2008; 17(2): 100–104.
  54. Rużczyńska M, Grabowska H. Nursing care of a patient with systemic lupus erythematosus using ICNP — a case study. Problemy Pielęgniarstwa. 2018; 26(1): 75–79.
  55. Jędryka-Góral A. The role of environmental factors in the etiology of systemic lupus erythematosus. Reumatologia. 2013; 1: 26–30.
  56. Borden MB, Parke AL. Antimalarial drugs in systemic lupus erythematosus: use in pregnancy. Drug Saf. 2001; 24(14): 1055–1063.
  57. Wang C, Fortin PR, Li Y, et al. Discontinuation of antimalarial drugs in systemic lupus erythematosus. J Rheumatol. 1999; 26(4): 808–815.
  58. Grygiel-Górniak B. Antimalarial drugs-are they beneficial in rheumatic and viral diseases?-considerations in COVID-19 pandemic. Clin Rheumatol. 2022; 41(1): 1–18.
  59. Majdan M. Toczeń rumieniowaty układowy. Zalecenia postępowania diagnostyczno-terapeutycznego. Reumatologia. 2016; 1: 26–35.
  60. Włochal M, Grzymisławski M. Hiperlipidemie wtórne — patogeneza i leczenie. Forum Zaburzeń Metabolicznych. 2016; 7(2): 69–78.
  61. Hüsing A, Kabar I, Schmidt HH. Lipids in liver transplant recipients. World J Gastroenterol. 2016; 22(12): 3315–3324.
  62. Pisano G, Fracanzani AL, Caccamo L, et al. Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study. World J Gastroenterol. 2016; 22(40): 8869–8882.
  63. Agencja Oceny Technologii Medycznych i Taryfikacji. Wydział Oceny Technologii Medycznych. Plaquenil (hydroksychlorochina): toczeń rumieniowaty układowy. Opracowanie na potrzeby oceny zasadności dalszego wydawania zgody na refundację. 2021.
  64. Kotyla PJ, Śliwińska-Kotyla B, Lewicki M, et al. Znaczenie inhibitorów hydroksymetyloglutarylo-koenzymu A (statyn) w reumatologii. Reumatologia. 2005; 43(1): 21–25.
  65. Lipmer M, Leavis HL. Statins for prevention of cardiovascular disease in systemic lupus erythematosus. Neth J Med. 2017; 75(3): 99–105.
  66. Pikto-Pietkiewicz W, Pasierski T. Ezetymib — inhibitor wchłaniania cholesterolu. Kardiologia Polska. 2006; 64: 1434–1441.